This is Part 3 of High-Risk HR-Positive, HER2-Negative Early-Stage Breast Cancer: Bridging Evidence, Risk Identification, and Real-World Practice, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.

 

In this video, Sara Tolaney, MD, MPH, FASCO, Erica Mayer, MD, MPH, FASCO, and Elahe Salehi, DNP, ANP-BC, discuss managing toxicities for patients with high-risk hormone receptor–positive, HER2-negative breast cancer on CDK4/6 therapy. They review the case of a 58-year-old woman with T2 N1 high-grade disease who develops grade 1 diarrhea after starting 150 mg of abemaciclib.

 

The faculty highlight practical approaches to establishing baseline bowel habits and optimizing supportive care, evidence supporting dose modification strategies that preserve efficacy, methods for monitoring renal function and cardiovascular risk during treatment, and the importance of frequent, proactive clinical monitoring.